-
Nov 21, 2024 | 
elsevier.com | Ann-Marie Roche
The InChI story is something like a Hollywood movie. It’s about the quest to encode the essential structural information of a chemical into a character string so it can be used, shared and found by any interested party. It features an unsung cast of quirky characters. And now, there’s even a happy ending that offers a new beginning for any organization seeking to pursue its chemical interests without sacrificing IP.
-
Oct 23, 2024 | 
elsevier.com | Ann-Marie Roche
We can safely use an overused word like “gamechanger” for ChatGPT. When released in November 2022, it triggered a revolutionary shift across many sectors, including R&D. However, two years later, while generative AI continues to evolve rapidly, we are still largely figuring out what these changes entail.
-
May 23, 2024 | 
elsevier.com | Ann-Marie Roche
With a PhD in organic chemistry and years of working with researchers in drug discovery to develop Elsevier’s data and information tools, Dr Catherine Nobanopens in new tab/window is now applying her know-how to advanced AI. As Lead Product Manager for Life Sciences Biomedical Innovation at Elsevier, she’s exploring innovative ways to better predict adverse drug reactions. “It’s very motivating to work on a project related to patient safety,” Catherine says.
-
Apr 10, 2024 | 
elsevier.com | Ann-Marie Roche
The recent hit HBO series The Last of Us(opens in new tab/window) — a post-apocalyptic story in which the planet has been ravaged by a terrifying fungal infection — has some people re-thinking their affection for mushrooms. But while fungi can have their downsides, they have long been not only a source of sustenance but of healing. Fungi have been used in traditional medicines for ages and eventually went on to become the source of that modern miracle: penicillin. Fungi are brimming with potential.
-
Mar 21, 2024 | 
elsevier.com | Ann-Marie Roche
The expression “data is the new gold” resonates with the people of Johnson Matthey(opens in new tab/window) — a global company that started as a gold assayer for the Bank of England in 1817. Now focused on sustainable technologies that are catalyzing the net zero transition, “JM” has just achieved a milestone in safeguarding its intellectual property and making it accessible for researchers and algorithms to trigger future innovation.
-
Feb 20, 2024 | 
elsevier.com | Ann-Marie Roche
SciBite’s Head of Ontologies talks about how her team is encoding scientific knowledge into software for the benefit of pharma and the public. As Head of Ontologies for SciBite, Dr Jane Lomax(opens in new tab/window) has an ambitious goal: to encode scientific knowledge into software so researchers can find and connect the information they need when they need it.
-
Jan 30, 2024 | 
elsevier.com | Ann-Marie Roche
It’s a riveting read: Chasing My Cure: A Doctor’s Race To Turn Hope Into Action(opens in new tab/window) is Dr David Fajgenbaum’s memoir about almost dying five times from idiopathic multicentric Castleman disease (iMCD) before discovering his own treatment in the form of a disused drug. His continued remission — 10 years and counting — means he can continue to focus on Every Cure(opens in new tab/window), a nonprofit he co-founded.
-
Jan 30, 2024 | 
elsevier.com | Ann-Marie Roche
It’s an enticing concept: recycling old drugs for new cures. It’s also viable: aspirin, Viagra and the new weight loss drug Wegovy are all repurposed drugs. And today, thanks to innovations in AI, we are accelerating the process — call it digital speed-dating that links a disease with its potential treatment. But what does using precision medicine for crop protection have to do with it? We talked to colleagues on Elsevier’s Professional Services team to find out.
-
Jan 17, 2024 | 
elsevier.com | Ann-Marie Roche
Challenges continue to mount for R&D-intensive companies. In addition to making sure they can rely on information and research — an issue we recently discussed in our articles The cost of fraudulent research and Fighting the problem of fraud in publishing — they are facing the ever-growing pressure of constantly adapting to the business environment. Evolving to meet the challenges of todayHistorically, R&D-intensive companies have focused their efforts in specific areas.
-
Jan 8, 2024 | 
elsevier.com | Ann-Marie Roche
Mark Sheehan is VP of Data Science for Elsevier’s Life Sciences team. His 20-plus years at the company map closely with the Elsevier’s digital journey. And today, pharmaceutical companies can follow a similar journey — albeit highly accelerated — using Elsevier’s latest AI-driven R&D boosters. We talked to Mark about his experiences along the way: from the joys of cracking open a newly printed book, to enabling R&D professionals to speedily crack new synthetic pathways at scale.
